ABL1 and acute lymphoblastic leukemia: However, because of the abnormal activation of bypassing pathways, monotherapy with either the first-generation ABL TKI imatinib or the second-generation ABL TKI dasatinib showed only a transient response to Ph+ B-ALL [49].